+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients



Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients



European Journal of Cancer 40(11): 1776-1786



The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24(+) NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54-62, 124-132 and 800-809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 012172506

Download citation: RISBibTeXText

PMID: 15251169

DOI: 10.1016/j.ejca.2004.04.003


Related references

Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib. Plos One 9(1): E86667, 2014

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clinical Cancer Research 14(3): 840-846, 2008

Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Research and Treatment 86(1): 19-29, 2004

Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology 5(12): 1939-1948, 2011

Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients. British Journal of Cancer 90(8): 1563-1571, April 19, 2004

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. Journal of Thoracic Oncology 6(11): 1895-1901, 2012

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Lung Cancer 87(3): 311-317, 2015

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study. Biomedical Journal 38(3): 221-228, 2016

Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis. Thoracic Cancer 2(3): 101-108, 2011

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Plos One 11(2): E0149722, 2016

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. Bmc Cancer 16(1): 868, 2017

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotargets and Therapy 10: 1955-1967, 2017

The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis. Translational Lung Cancer Research 4(6): 792-796, 2016

The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation. Zhonghua Jie He He Hu Xi Za Zhi 41(10): 778-782, 2018

450Pimpact of baseline, trend, and normalization of carcinoembryonic antigen on survival in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors. Annals of Oncology 26(suppl 9): ix138.1-ix138, 2015